3501 related articles for article (PubMed ID: 18539916)
21. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
22. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
[TBL] [Abstract][Full Text] [Related]
23. Treating diabetes today with gliclazide MR: a matter of numbers.
Avogaro A
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():14-9. PubMed ID: 22118706
[TBL] [Abstract][Full Text] [Related]
24. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
[TBL] [Abstract][Full Text] [Related]
25. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
26. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
27. Intensive glucose control and macrovascular outcomes in type 2 diabetes.
; Turnbull FM; Abraira C; Anderson RJ; Byington RP; Chalmers JP; Duckworth WC; Evans GW; Gerstein HC; Holman RR; Moritz TE; Neal BC; Ninomiya T; Patel AA; Paul SK; Travert F; Woodward M
Diabetologia; 2009 Nov; 52(11):2288-98. PubMed ID: 19655124
[TBL] [Abstract][Full Text] [Related]
28. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
30. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
31. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
32. Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Selvin E; Wang D; McEvoy JW; Juraschek SP; Lazo M; Hamet P; Cooper ME; Marre M; Williams B; Harrap S; Chalmers J; Woodward M
Diabetes Obes Metab; 2019 Aug; 21(8):2017-2023. PubMed ID: 31050156
[TBL] [Abstract][Full Text] [Related]
33. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
34. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
36. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Hassan MH; Abd-Allah GM
Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
38. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
39. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
40. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
